Autopsy report · NCT02681302

Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence

“Lack of Accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 7 years 11 months before it stopped.
• 46 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Hackensack Meridian Health

Sponsor type

University, hospital or other

Conditions

Multiple Myeloma; Lymphoma

Interventions

Ipilimumab; Nivolumab

Participants

46

Sites

2

Countries

United States

Trials that died the same way

• Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma
  “Lack of adequate accrual.” (92% match in meaning)
• Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth
  “Inadequate accrual” (90% match in meaning)
• Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
  “Severe lack of accrual” (90% match in meaning)
• Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme
  “poor accrual” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.